Former VP at Senseonics Holdings Inc
- Recent trends and developments in the CGM (continuous glucose monitoring) device market and strategies to penetrate type 1 and type 2 diabetes populations
- Competitive landscape and product differentiation – Dexcom’s (NASDAQ: DXCM) G7, Medtronic’s (NYSE: MDT) MiniMed and Abott’s (NYSE: ABT) Freestyle Libre 3, including compatibility with pumps, usability and other features to meet changing patient demands
- Quality control outlook for Medtronic's MiniMed device and expectations for a new sensor in 2024
- Potential threats for CGM market disruption, including emerging players and increase of weight loss drug use for the type 2 population
- Global CGM global market opportunity and successful go-to-market dynamics
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.